Literature DB >> 22291025

Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface.

Chantevy Pou1, Clotilde Mannoury la Cour, Leigh A Stoddart, Mark J Millan, Graeme Milligan.   

Abstract

Human dopamine D(2long) and D(3) receptors were modified by N-terminal addition of SNAP or CLIP forms of O(6)-alkylguanine-DNA-alkyltransferase plus a peptide epitope tag. Cells able to express each of these four constructs only upon addition of an antibiotic were established and used to confirm regulated and inducible control of expression, the specificity of SNAP and CLIP tag covalent labeling reagents, and based on homogenous time-resolved fluorescence resonance energy transfer, the presence of cell surface D(2long) and D(3) receptor homomers. Following constitutive expression of reciprocal constructs, potentially capable of forming and reporting the presence of cell surface D(2long)-D(3) heteromers, individual clones were assessed for levels of expression of the constitutively expressed protomer. This was unaffected by induction of the partner protomer and the level of expression of the partner required to generate detectable cell surface D(2long)-D(3) heteromers was defined. Such homomers and heteromers were found to co-exist and using a reconstitution of function approach both homomers and heteromers of D(2long) and D(3) receptors were shown to be functional, potentially via trans-activation of associated G protein. These studies demonstrate the ability of dopamine D(2long) and D(3) receptors to form both homomers and heteromers, and show that in cells expressing each subtype a complex mixture of homomers and heteromers co-exists at steady state. These data are of potential importance both to disorders in which D(2long) and D(3) receptors are implicated, like schizophrenia and Parkinson disease, and also to drugs exerting their actions via these sites.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22291025      PMCID: PMC3308812          DOI: 10.1074/jbc.M111.326678

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.

Authors:  J N Joyce
Journal:  Synapse       Date:  2001-05       Impact factor: 2.562

2.  Dopamine D2 receptor dimer formation: evidence from ligand binding.

Authors:  D Armstrong; P G Strange
Journal:  J Biol Chem       Date:  2001-02-23       Impact factor: 5.157

3.  Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids.

Authors:  Xian-Yu Liu; Zhong-Chun Liu; Yan-Gang Sun; Michael Ross; Seungil Kim; Feng-Fang Tsai; Qi-Fang Li; Joseph Jeffry; Ji-Young Kim; Horace H Loh; Zhou-Feng Chen
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

Review 4.  Neuronal Gq/11-coupled dopamine receptors: an uncharted role for dopamine.

Authors:  Asim J Rashid; Brian F O'Dowd; Vaneeta Verma; Susan R George
Journal:  Trends Pharmacol Sci       Date:  2007-10-22       Impact factor: 14.819

5.  G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors.

Authors:  J Robert Lane; Ben Powney; Alan Wise; Stephen Rees; Graeme Milligan
Journal:  J Pharmacol Exp Ther       Date:  2008-01-24       Impact factor: 4.030

Review 6.  Asymmetry of GPCR oligomers supports their functional relevance.

Authors:  Pascal Maurice; Maud Kamal; Ralf Jockers
Journal:  Trends Pharmacol Sci       Date:  2011-06-28       Impact factor: 14.819

7.  Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A).

Authors:  M Pfeiffer; T Koch; H Schröder; M Klutzny; S Kirscht; H J Kreienkamp; V Höllt; S Schulz
Journal:  J Biol Chem       Date:  2000-12-27       Impact factor: 5.157

8.  Dopamine D2 receptors form higher order oligomers at physiological expression levels.

Authors:  Wen Guo; Eneko Urizar; Michaela Kralikova; Juan Carlos Mobarec; Lei Shi; Marta Filizola; Jonathan A Javitch
Journal:  EMBO J       Date:  2008-09-03       Impact factor: 11.598

9.  Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation.

Authors:  Roberto Maggio; Francesca Novi; Mario Rossi; Giovanni U Corsini; Mark J Millan
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

Review 10.  Novel pharmacological applications of G-protein-coupled receptor-G protein fusions.

Authors:  Graeme Milligan; Geraldine Parenty; Leigh A Stoddart; J Robert Lane
Journal:  Curr Opin Pharmacol       Date:  2007-08-06       Impact factor: 5.547

View more
  19 in total

Review 1.  Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Authors:  Melissa L Perreault; Ahmed Hasbi; Brian F O'Dowd; Susan R George
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

2.  Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55.

Authors:  Timothy H C Cheung; Amy L Loriaux; Suzanne M Weber; Kayla N Chandler; Jeffrey D Lenz; Romina F Schaan; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  J Pharmacol Exp Ther       Date:  2013-09-09       Impact factor: 4.030

Review 3.  The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs.

Authors:  Mario Rossi; Irene Fasciani; Francesco Marampon; Roberto Maggio; Marco Scarselli
Journal:  Mol Pharmacol       Date:  2017-03-06       Impact factor: 4.436

Review 4.  The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization.

Authors:  Graeme Milligan
Journal:  Mol Pharmacol       Date:  2013-04-30       Impact factor: 4.436

Review 5.  Lanthanide-Based Optical Probes of Biological Systems.

Authors:  Ukrae Cho; James K Chen
Journal:  Cell Chem Biol       Date:  2020-07-30       Impact factor: 8.116

6.  Reinterpreting anomalous competitive binding experiments within G protein-coupled receptor homodimers using a dimer receptor model.

Authors:  Verònica Casadó-Anguera; Estefanía Moreno; Josefa Mallol; Sergi Ferré; Enric I Canela; Antoni Cortés; Vicent Casadó
Journal:  Pharmacol Res       Date:  2018-11-22       Impact factor: 7.658

Review 7.  Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.

Authors:  Gerhard Gross; Karsten Wicke; Karla U Drescher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-06       Impact factor: 3.000

Review 8.  Glioblastoma treatment using perphenazine to block the subventricular zone's tumor trophic functions.

Authors:  R E Kast; B M Ellingson; C Marosi; M-E Halatsch
Journal:  J Neurooncol       Date:  2013-11-17       Impact factor: 4.130

9.  Analysis of Human Dopamine D3 Receptor Quaternary Structure.

Authors:  Sara Marsango; Gianluigi Caltabiano; Chantevy Pou; María José Varela Liste; Graeme Milligan
Journal:  J Biol Chem       Date:  2015-04-30       Impact factor: 5.157

10.  Distinct Agonist Regulation of Muscarinic Acetylcholine M2-M3 Heteromers and Their Corresponding Homomers.

Authors:  Despoina Aslanoglou; Elisa Alvarez-Curto; Sara Marsango; Graeme Milligan
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.